SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: arnie h who wrote (1510)10/24/1998 4:56:00 PM
From: Steve Johnston  Respond to of 2173
 
Maybe they will do a reverse split (aka stock consolidation) to bring the price back up to NASDAQ minimums? Any thoughts?



To: arnie h who wrote (1510)10/26/1998 10:31:00 AM
From: Rudy Saucillo  Read Replies (2) | Respond to of 2173
 
Arnie,

My take is that interest in a buyout would be based on the potential for their Exendin-4 program. That is, results of preclinical studies to date, the status of their license/patent position, and competition from others developing GLP-1 analogs and from others developing related therapeutics.

Tough question and very difficult to place a value on the Exendin program at this early stage.

Rudy


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News